KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Nektar Therapeutics (NKTR) over the last 15 years, with Q3 2025 value amounting to 0.52%.

  • Nektar Therapeutics' Return on Capital Employed rose 700.0% to 0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.36% for FY2024, which is 1600.0% up from last year.
  • Nektar Therapeutics' Return on Capital Employed amounted to 0.52% in Q3 2025, which was up 700.0% from 0.63% recorded in Q2 2025.
  • Nektar Therapeutics' Return on Capital Employed's 5-year high stood at 0.29% during Q1 2021, with a 5-year trough of 0.71% in Q4 2023.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.55% (2025), whereas its average is 0.53%.
  • As far as peak fluctuations go, Nektar Therapeutics' Return on Capital Employed tumbled by -2500bps in 2022, and later soared by 2800bps in 2024.
  • Over the past 5 years, Nektar Therapeutics' Return on Capital Employed (Quarter) stood at 0.4% in 2021, then plummeted by -38bps to 0.56% in 2022, then decreased by -29bps to 0.71% in 2023, then soared by 40bps to 0.43% in 2024, then fell by -21bps to 0.52% in 2025.
  • Its Return on Capital Employed was 0.52% in Q3 2025, compared to 0.63% in Q2 2025 and 0.55% in Q1 2025.